Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).
Br J Cancer
; 130(2): 224-232, 2024 02.
Article
in En
| MEDLINE
| ID: mdl-37973958
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antiemetics
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
Br J Cancer
Year:
2024
Document type:
Article
Affiliation country:
Japón